CDK4/6 Inhibitors in the Treatment of Patients with Breast Cancer: Summary of a Multidisciplinary Round-table Discussion

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2018 Sep 1

PMID 30167331

Citations 23

Authors

Matthias Preusser

Leticia De Mattos-Arruda

Marc Thill

Carmen Criscitiello

Rupert Bartsch

Thomas Ruhstaller

Evandro de Azambuja

Christoph C Zielinski

Affiliations

Soon will be listed here.

Abstract

This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be.

Citing Articles

Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant.

Robert N, Chen C, Doan J, Venkatasetty D, Espirito J, Aguilar K Future Oncol. 2025; 21(1):83-94.

PMID: 39810652 PMC: 11759524. DOI: 10.1080/14796694.2024.2442302.

Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer.

Awada A, Ahmad S Curr Oncol. 2024; 31(9):5374-5383.

PMID: 39330025 PMC: 11431580. DOI: 10.3390/curroncol31090397.

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.

Goetz M, Hamilton E, Campone M, Hurvitz S, Cortes J, Johnston S Clin Cancer Res. 2023; 30(10):2233-2244.

PMID: 37889120 PMC: 11094424. DOI: 10.1158/1078-0432.CCR-22-3573.

Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer.

Khorrami M, Viswanathan V, Reddy P, Braman N, Kunte S, Gupta A NPJ Breast Cancer. 2023; 9(1):67.

PMID: 37567880 PMC: 10421862. DOI: 10.1038/s41523-023-00574-7.

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.

Navarro-Yepes J, Kettner N, Rao X, Bishop C, Bui T, Wingate H Cancer Res. 2023; 83(19):3264-3283.

PMID: 37384539 PMC: 10592446. DOI: 10.1158/0008-5472.CAN-23-0705.

References

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts R, Pearson A, Tarazona N . Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015; 7(313):313ra182. PMC: 4998737. DOI: 10.1126/scitranslmed.aac7551. View

Murphy C, Dickler M . Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocr Relat Cancer. 2016; 23(8):R337-52. DOI: 10.1530/ERC-16-0121. View

Fu X, Osborne C, Schiff R . Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast. 2013; 22 Suppl 2:S12-8. PMC: 3808116. DOI: 10.1016/j.breast.2013.08.001. View

Asghar U, Witkiewicz A, Turner N, Knudsen E . The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015; 14(2):130-46. PMC: 4480421. DOI: 10.1038/nrd4504. View

Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios C . 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017; 28(12):3111. PMC: 5834023. DOI: 10.1093/annonc/mdx036. View

Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C . Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994; 54(7):1812-7. View

Baselga J, Campone M, Piccart M, Burris 3rd H, Rugo H, Sahmoud T . Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2011; 366(6):520-9. PMC: 5705195. DOI: 10.1056/NEJMoa1109653. View

Di Cosimo S, Baselga J . Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol. 2010; 7(3):139-47. DOI: 10.1038/nrclinonc.2009.234. View

Goel S, Wang Q, Watt A, Tolaney S, Dillon D, Li W . Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016; 29(3):255-269. PMC: 4794996. DOI: 10.1016/j.ccell.2016.02.006. View

10.

Miller T, Rexer B, Garrett J, Arteaga C . Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011; 13(6):224. PMC: 3315683. DOI: 10.1186/bcr3039. View

11.

McGuire W, Horwitz K, Pearson O, SEGALOFF A . Current status of estrogen and progesterone receptors in breast cancer. Cancer. 1977; 39(6 Suppl):2934-47. DOI: 10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p. View

12.

Goetz M, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J . MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35(32):3638-3646. DOI: 10.1200/JCO.2017.75.6155. View

13.

Sighoko D, Liu J, Hou N, Gustafson P, Huo D . Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?. Oncologist. 2014; 19(6):592-601. PMC: 4041672. DOI: 10.1634/theoncologist.2013-0427. View

14.

Toy W, Shen Y, Won H, Green B, Sakr R, Will M . ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013; 45(12):1439-45. PMC: 3903423. DOI: 10.1038/ng.2822. View

15.

Vora S, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C . CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014; 26(1):136-49. PMC: 4155598. DOI: 10.1016/j.ccr.2014.05.020. View

16.

Curtin J, Fridlyand J, Kageshita T, Patel H, Busam K, Kutzner H . Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20):2135-47. DOI: 10.1056/NEJMoa050092. View

17.

Kenny F, Hui R, Musgrove E, Gee J, Blamey R, Nicholson R . Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res. 1999; 5(8):2069-76. View

18.

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S . Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016; 375(18):1738-1748. DOI: 10.1056/NEJMoa1609709. View

19.

Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C . Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget. 2016; 7(46):74448-74459. PMC: 5342678. DOI: 10.18632/oncotarget.12950. View

20.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M . Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008; 26(10):1664-70. DOI: 10.1200/JCO.2007.13.5822. View